Enrolling

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)

I6T-MC-AMBA -

The main purpose of this study is to investigate the efficacy, pharmacokinetics, and safety of mirikizumab in pediatric participants with moderately to severely active Ulcerative Colitis (UC).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
2 - 17 years
Conditions the trial is for
Ulcerative Colitis
What the trial is testing?
LY3074828
Could I receive a Placebo?
No
Enrollment Goal
60
Trial Dates
Nov 22, 2023 - Mar 2027
How long will I be in the trial?
The study will last approximately 72 weeks and may include up to 19 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Males or females weighing >10 kg and ≥2 and <18 years old

  • Have moderate to severe ulcerative colitis

  • Have failed other treatments for UC

  • Have U at least 3 months

Participants Must Not:

  • Have Crohn’s disease or certain liver diseases

  • Have immune deficiency syndrome

  • Had small bowel surgery in the last 6 months

  • Have cancer of the intestinal tract

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources